From Financial Modeling Prep: 2025-03-21 09:00:00

VolitionRx Limited, listed on NYSE American as VNRX, is gearing up to announce its quarterly earnings. Analysts project an EPS loss of $0.06 and revenue around $545,340 for the company known for its Nu.Q® Cancer diagnostics test.

The innovative Nu.Q® Cancer test by VolitionRx can detect 21 types of human cancers, positioning the company as a potential leader in the $20 billion liquid biopsy industry. Its low-cost and high specificity make it a promising tool in cancer diagnosis.

VolitionRx is focusing on the lung cancer market with its Nu.Q® Cancer Test, aiming to revolutionize the $4 billion industry. The test offers a cost-effective and simple solution for diagnosing, treating, and monitoring lung cancer, requiring only a small blood sample for analysis.

A clinical study at National Taiwan University Hospital is underway to validate VolitionRx’s Nu.Q® Lung Cancer Test. The study, involving 500 patients, seeks to differentiate between malignant and benign pulmonary nodules, showing promise in distinguishing nodules detected through LDCT screening.

Despite its groundbreaking innovations, VolitionRx faces financial hurdles. With a negative P/E ratio of -1.60 and a current ratio of 0.22, the company may encounter profitability and liquidity challenges. Its price-to-sales and enterprise value to sales ratios also indicate a high valuation relative to sales.



Read more at Financial Modeling Prep:: VolitionRx Limited’s Upcoming Earnings and Innovat…